Intelligent Bio Solutions Inc. (INBS) stock
INBSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3057% below fair value
$1.54−0.02 (-1.28%)
Close on Nov 18, 2026Market cap $4.66MP/E –Yield –
Intelligent Bio Solutions revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Intelligent Bio Solutions's revenue for the twelve months ending Jun 30, 2026 was $4.22M, up 38.1% year over year. For fiscal 2026 it was $4.22M, up 38.1% from the year before. The highest annual figure on record is $4.22M in fiscal 2026.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $4.22M | +38.1% |
| FY2025 | Jun 30, 2025 | $3.05M | -1.9% |
| FY2024 | Jun 30, 2024 | $3.11M | +147.6% |
| FY2023 | Jun 30, 2023 | $1.26M | +187.5% |
| FY2022 | Jun 30, 2022 | $437.15K | -77.9% |
| FY2021 | Jun 30, 2021 | $1.98M | +949.3% |
| FY2020 | Jun 30, 2020 | $188.74K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $1.15M | +35.8% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $1.06M | +45.5% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $896.77K | +47.6% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $1.11M | +27.5% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $843.88K | +121.5% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $728.87K | -19.7% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $607.49K | -33.8% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $872.29K | -3.7% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $380.91K | -14.0% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $907.64K | +98.6% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $917.27K | +157.2% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $905.97K | +191.0% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $443.14K | +562.8% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $457.06K | +137.4% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $356.68K | +100.6% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $311.32K | -80.6% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $66.86K | +95.0% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $192.50K | -32.0% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $177.79K | +220.8% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $1.61M | +2230.0% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $34.29K | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $283.04K | – |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $55.43K | – |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $69.00K | – |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -$1.53K | – |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -$798 | – |
See a number that looks wrong?